Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Main Capital and Optimizers group in connection with the acquisition of Vendre
Mandate

Vinge advises Main Capital and Optimizers group in connection with the acquisition of Vendre

January 30, 2023 Employment and Benefits Commercial Agreements Intellectual Property M&A IT, Telecommunications and Outsourcing Data protection and processing of personal data

Vendre is a provider of an innovative module-based eCommerce platform for customers in both B2B and B2C markets

Vendre AB was founded in 2007 and provides an innovative eCommerce platform with several different and unique functionalities to its over one hundred customers. Through the acquisition, Main Capital’s portfolio company Optimizers strengthens its product offering and position in the Nordic market, growing towards EUR 25 million in revenues and 170 employees.

Vinge’s team mainly consisted of Filip Öhrner, Olivia Belding, Nando Basic (M&A), Ebba Svenburg (Employment), Martin Boström (Commercial Agreements) Lisa Hörnqvist (IT and GDPR), Rebecka Målquist, Johan Gavelin (IP) and Ellinore Boström Andersson (project assistant).

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026